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Abstract
Background: Excessive accumulation of bilirubin contributes to neonatal hyperbilirubinemia in
rats. Heme oxygenase (HO) is one of the rate-limiting enzymes in catabolizing heme to bilirubin. In
the present study, we investigated whether suppression of rat HO-1 (rHO-1) expression by small
interference RNAs (siRNAs) reduces bilirubin levels in hyperbilirubinemic rats.
Results:  Four pairs of siRNA targeting rHO-1 mRNA were introduced into BRL cells and
compared for their inhibitory effect on the expression of rHO-1 gene and production of rHO-1
protein. The siRNA exhibiting the most potent effect on HO-1 expression and activity was then
administered intraperitoneally to 7 to 9-day-old rats with hyperbilirubinemia. The siRNA
distributed mostly in the liver and spleen of neonatal rat. Serum bilirubin levels and hepatic HO-1
expression were further evaluated. Systemic treatment of siRNA targeting rHO-1 reduced hepatic
HO-1 expression and decreased the serum bilirubin levels in a time- and dose-dependent manner,
and siRNA decreased the indirect bilirubin levels more effectively than Sn-protoporphyrin (SnPP),
an HO-1 inhibitor.
Conclusion: siRNA targeting rHO-l attenuates hepatic HO-1 expression and serum bilirubin
levels. Thus this study provides a novel therapeutic rationale for the prevention and treatment of
neonatal hyperbilirubinemia.
Background
Neonatal hyperbilirubinemia is a common medical con-
dition in newborn mammalian. About 60% term infants
and 80% preterm infants develop hyperbilirubinemia
within one week after birth. Neonatal hyperbilirubinemia
is mainly due to the accumulation of bilirubin as a result
of metabolic disturbance caused by various factors. Nor-
mally, serum bilirubin levels increase within 3 to 5 days
after birth, and then begin to decline [1]. However, under
pathologic states, serum bilirubin, especially indirect
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bilirubin, can reach an exceedingly high level which leads
to neurotoxicity, namely kernicterus, and eventually
results in permanent neurological damage or even death
[2].
Bilirubin is produced by the degradation of heme. Heme
oxygenase (HO) is the initial and rate-limiting enzyme in
this catabolic process. HO consists of three isozymes: HO-
1, HO-2 and HO-3. Heme released from degraded fetal
red blood is a potent inducer of HO-1 in the neonatal
period, which is responsible for the increase of serum
bilirubin levels and the development of hyperbilirubine-
mia. Inhibition of HO-1 expression or its enzymatic activ-
ity concurs to the reduction of bilirubin levels [3].
Therefore, it is plausible to target HO-1 as a novel thera-
peutic rationale for the treatment of neonatal hyperbiliru-
binemia. In this study, we aimed to assess the efficacy of
direct inhibition of bilirubin production by suppressing
HO-1 in a neonatal rat hyperbilirubinemia model.
Small interference RNA (siRNA) technology utilizes short
double-stranded RNA to specifically inhibit the transcrip-
tion of a given target gene [4]. This technique has been
proven to be a promising method in treating a number of
diseases, such as hereditary diseases, viral hepatitis, and
certain cancers [5]. Furthermore, RNA interference as a
means of treating age-related macular degeneration has
entered into a clinical trial [6]. These advances provide a
theoretical and experimental basis to treat neonatal hyper-
bilirubinemia using siRNA. Previously, we demonstrated
that siRNA specifically inhibits the expression of human
HO-1 (hHO-1) in human liver cell line HL-7702 [7]. In
this paper, methoxyl siRNA targeting rat HO-1 (rHO-1)
mRNA was used to suppress HO-1 in neonatal hyperbi-
lirubinemia rat model. This study tested the feasibility of
preventing and treating neonatal hyperbilirubinemia and
bilirubin toxic encephalopathy by targeting HO-1 gene.
Results
siRNA Transfection Efficiency
To determine the transfection efficiency of siRNA, a car-
boxy-fluorescein (FAM) labeled negative control (NC)-
siRNA was transfected into BRL cells, and the nuclei were
stained with 4',6-diamidino-2-phenylindole (DAPI) after
6 hours. Confocal microscopy showed that 6 hours post-
transfection, siRNA entered the cells and primarily distrib-
uted in the cytoplasm (Figure 1A to 1C). Furthermore,
flow cytometry demonstrated the siRNA transfection effi-
ciency in BRL cells was up to 90% (Figure 1D and 1E).
Down-Regulation of rHO-1 Gene Expression by siRNA
Quantitative gel gray scale scanning was used to compare
the inhibitory effect of four pairs of siRNA targeting the
rHO-1 gene. siRNA-4 showed the most potent inhibition
on rHO-1 mRNA expression (greater than 75%, Figure 2).
Therefore, siRNA-4 was selected for the rest of the experi-
ments.
Dose- and Time-Dependent Down-Regulation of rHO-1 by 
siRNA
BRL cells were transfected with 1, 10 and 50 nmol/L
siRNA-4, respectively, and collected at 24 hours post-
transfection. RT-PCR was performed to determine the
HO-1 mRNA level. The expression of rHO-1 in the BRL
cells transfected with 1, 10 and 50 nmol/L siRNA were
inhibited approximately 30%, 72% and 80%, respec-
tively. Thus, the inhibitory effect of siRNA-4 on rHO-1
exhibited a dose-dependent relationship (Figure 3A and
3B).
Ten nmol/L siRNA-4 was transfected into BRL cells, and
the rHO-1 expression was examined at 15, 24 and 48
hours post-transfection as demonstrated in Figure 3C and
3D. The maximum inhibitory effect of siRNA-4 was
observed at 24 hours.
Effect of Hemin and siRNA on rHO-1 Protein
Hemin, an HO-1 inducer, was selected to induce the
expression of rHO-1. BRL cells were incubated with 1.5,
Detection of siRNA transfection efficiency Figure 1
Detection of siRNA transfection efficiency. Fifty nmol/
L FAM labeled NC-siRNA was transfected into the cells for 6 
hours. The nuclei were stained with DAPI. Confocal micros-
copy (×60) and flow cytometry were employed to detect the 
transfection efficiency (upper figure A, B and C), siRNA 
entered the cells, and primarily distributed in the cytoplasm. 
The lower figure was the result from flow cytometric analy-
sis, D contained untransfected cells, E contained FAM-siRNA 
transfected cells. The results were analyzed with Win MDI29 
software, which indicated that the siRNA transfection effi-
ciency in BRL cells was approximately 90%.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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4.5 and 15 μmol/L hemin, and collected 18 hours post-
induction. The level of rHO-1 protein was determined by
Western Blot analysis. Hemin induced rHO-1 in a dose-
dependent manner. However, cell toxicity was observed at
the higher concentrations of hemin. Thus, 4.5 μmol/L was
selected as the working concentration for rHO-1 induc-
tion (Figure 4A). Cells treated with 4.5 μmol/L hemin for
18, 24 and 36 hours were collected to determine the level
of rHO-1 protein by Western Blot analysis. Eighteen hours
after induction, rHO-1 level peaked and then declined
over time. Therefore, the optimized induction time of
rHO-1 by hemin was determined to be18 hours
(Figure 4B).
The inhibitory effect of siRNA-4 on rHO-1 is shown in Fig-
ure 5A and 5B. Compared with the negative control,
siRNA inhibited the hemin-induced expression of HO-1
in a time-dependent manner. The inhibitory effect of
siRNA reached the maximum level of 64% at 36 hours
post-transfection.
Effect of siRNA-4 on Enzymatic Activity of rHO-1
In order to verify our assumption that the suppression of
HO-1 will ultimately lead to a reduction of bilirubin in
vitro, homogenates from BRL cells transfected with and
without siRNA-4 were used to measure bilirubin produc-
tion by the rHO-1 enzymatic assay. The activity of rHO-1
treated with hemin and siRNA-4 was 3.33 ± 0.17 and 2.31
± 0.17 nmol bilirubin mg protein-1  h-1, respectively
(Table 1).
Distribution of FAM-siRNA in Neonatal Rat
To confirm the targeting effect of siRNA in vivo, FAM
labeled siRNA-4 was injected intraperitoneally into 7-day-
old neonatal Sprague-Dawley (SD) rats. Confocal micros-
copy showed the distribution of fluorescence in the tis-
sues at 6, 24 and 48 hours after injection, and the siRNA
distributed predominantly in the liver and spleen
(Figure 6).
The inhibitory effect of four pairs of siRNAs on HO-1 mRNA Figure 2
The inhibitory effect of four pairs of siRNAs on HO-1 
mRNA. Four pairs of double-strand siRNAs were trans-
fected into BRL cell for 24 hours. rHO-1 mRNA levels were 
analyzed by RT-PCR and were found to be reduced by more 
than 75% by siRNA-4, 57% by siRNA-1, and 42% by siRNA-2. 
siRNA-3 did not exhibit any significant inhibitory effect. A: 
Results of RT-PCR. B. Statistical analysis. Data represent the 
results from three independent experiments. *P < 0.01, com-
pared with NC-siRNA group.
Dose- and time-dependent down-regulation of rHO-1 by  siRNA Figure 3
Dose- and time-dependent down-regulation of rHO-1 
by siRNA. A and B. The dose-dependent inhibitory effect of 
siRNA (*P < 0.01, compared with untransfected controls). 
The doses of siRNA used in the experiments were 0 nmol/L, 
1 nmol/L, 10 nmol/L and 50 nmol/L. C and D. Time-depend-
ent inhibitory effect of siRNA. The time points were 15 
hours, 24 hours and 48 hours at a siRNA dose of 10 nmol/L. 
The maximum inhibitory effect of siRNA-4 was observed at 
24 hours. (*P < 0.01 or **P < 0.05). The results represent 
values derived from three independent experiments.
Effect of hemin on rHO-1 protein Figure 4
Effect of hemin on rHO-1 protein. A. The effect of 
hemin at different concentrations on the level of HO-1 pro-
tein. BRL cells were treated with 1.5 μmol/L, 4.5 μmol/L and 
15 μmol/L hemin to induce the HO-1 expression, result of 
Western Blot 18 hours after the treatment indicated that the 
level of HO-1 protein was in a hemin dose-dependent way to 
increase. B. The change of HO-1 protein level induced by 4.5 
μmol/L hemin at different time points. Eighteen hours after 
treatment with hemin, the level of HO-1 protein reached its 
peak.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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Dose- and Time-Dependent Reduction of the Serum 
Bilirubin and rHO-1 Levels by siRNA in a Neonatal 
Hyperbilirubinemia Rat Model
In light of the in vitro results, we sought to determine if
siRNA inhibited serum bilirubin in vivo. Seven to 9-day-
old SD rats were administered intraperitoneally with δ-
aminolevulinic acid (ALA) 50 μmol/100 g body weight
(bw) to induce hyperbilirubinemia. Western Blot analysis
showed that the level of HO-1 significantly increased in
the liver of these rats (Figure 7A). This is consistent with
recent reports in the literature [3]. In addition, the levels
of serum total bilirubin, direct bilirubin and indirect
bilirubin all increased (Figure 7B). This suggests that we
have successfully established a rat model of neonatal
hyperbilirubinemia.
Western Blot analysis revealed that in vivo siRNA-4 treat-
ment reduced rHO-1 product in the liver in a concentra-
tion-dependent manner (Figure 8A and 8B). The levels of
total, direct and indirect bilirubin decreased considerably
after siRNA-4 injection at doses of 5 OD/20 g and 10 OD/
20 g bw (Figure 8C). This effect was concentration-
dependent. However, the decrease of total, direct and
indirect bilirubin was not significant at 3 OD/20 g bw
(Figure 8C). In rats treated intraperitoneally with 10 OD/
20 g bw of siRNA-4 for three times, no abnormal behavior
was observed. The changes of both serum bilirubin and
rHO-1 indicate that the effective treatment time of siRNA-
4 was 48 hours because the inhibitory effect decreased at
72 hours. The control group showed no significant change
in either bilirubin levels or rHO-1 in the liver, suggesting
the inhibitory effect of siRNA-4 is HO-1 specific (Figure
9A to 9C).
Effect of siRNA and SnPP in a Neonatal 
Hyperbilirubinemia Rat Model
We next compared the suppressive effect of siRNA and Sn-
protoporphyrin (SnPP, an HO-1 inhibitor) on the rat neo-
natal model of hyperbilirubinema. Serum bilirubin levels
of rats treated by siRNA-4 and SnPP were significantly
attenuated compared with the control group. However,
siRNA-4 exhibited more inhibitory effect on indirect
bilirubin than SnPP (Figure 10A).
Real-time PCR also showed that HO-1 level in the liver
significantly decreased in the rats treated with siRNA-4 but
not in those treated with SnPP (Figure 10B). These results
reveal that SnPP possesses a dual role: it could up-regulate
HO-1 expression but significantly inhibit HO-1 activity.
Discussion
Bilirubin exerts a mixture of helpful and harmful effects.
Positive effects include its role as an anti-oxidant and anti-
inflammatory agent [8,9]. However, the abnormal
increase of total serum bilirubin, particularly indirect
bilirubin (unconjugated bilirubin) in the neonatal period
can cause devastating neurological complications. Indi-
rect bilirubin, a lipid-soluble molecule, is taken up by
hepatic cells and transformed into glucuronic acid
bilirubin (direct bilirubin) in the presence of UDP-glu-
curonyl transferase. Lipid-soluble indirect bilirubin can
penetrate the cell membrane and the blood brain barrier,
leading to neonatal kernicterus, whose central nervous
Effect of siRNA-4 on hemin-induced HO-1 protein level Figure 5
Effect of siRNA-4 on hemin-induced HO-1 protein 
level. BRL cells were transfected with 10 nmol/L siRNA-4 
and collected at 24, 36 and 48 hours respectively after the 
transfection. Eighteen hours before the collection, 4.5 μmol/
L hemin was added into all the groups to induce HO-1 
expression. Compared to the blank group, the inhibitory 
rates of siRNA to HO-1 at 24, 36 and 48 hours after trans-
fection were 53%, 64% and less than 30%, respectively. * P < 
0.01 or ** P < 0.05 A. Results of Western Blot. B. Statistical 
results. Data represent the results from three independent 
experiments.







Enzymatic activity (Units) 1.15 ± 0.07 1.35 ± 0.07 0.95 ± 0.06
Specific activity (nmol bilirubin mg protein-1 h-1) 2.62 ± 0.16 3.33 ± 0.17* 2.31 ± 0.17
* P < 0.05, compared with control groupBMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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system sequelae reflect both a predilection of bilirubin
toxicity for neurons (rather than glial cells) and the
regional topography of bilirubin-induced neuronal injury
involving prominent basal ganglia, cochlear and oculo-
motor nuclei [10].
Currently, the treatments for neonatal hyperbilirubinne-
mia are traditional phototherapy, exchange transfusion
and drug treatment [11-13]. Although these treatments
are effective, they are limited to removing excessive
bilirubin rather than preventing the production of
bilirubin. Bilirubin is a product of complex heme metab-
olism that requires the participation of a series of key
enzymes. HO is an inducible, rate-limiting enzyme in the
production of bilirubin. ALA is a heme precursor which
can rapidly and consistently cause elevation of the serum
bilirubin levels. Concurrent with increasing bilirubin,
hepatic heme oxygenase activity increases considerably
due to the increased availability of ALA-derived heme [3].
Recently, HO-1 has become a novel therapeutic target for
attempts to reduce bilirubin production. Sn-mesoporphy-
rin (SnMP) and SnPP, which are structural analogs of
heme, competitively inhibit HO enzymatic activity and
consequently decrease the synthesis of bilirubin [14].
Clinical trials have demonstrated that SnMP effectively
prevents hyperbilirubinemia caused by premature birth
and hemolysis [15,16]. However, the inhibitory mecha-
nism of SnMP on hyperbilirubinemia in vivo is uncertain
[17]. Therefore, the safety issue concerning the applica-
tion of this compound in clinics remains to be fully stud-
ied.
In this study, we investigated whether siRNAs can effec-
tively inhibit HO-1 expression that is up-regulated by
hemin under hyperbilirubinemia conditions. Recent
progress in siRNA technology provides a novel means to
treat many diseases including hyperbilirubinemia. siRNA
shows a superior specificity and stability compared with
antisense RNA [18-20]. Since HO-1 is an inducible
enzyme, targeted suppression by siRNA is a promising
therapeutic approach to suppress HO-1 both in vitro and
in vivo.
We first compared four pairs of siRNAs for their effects on
inhibiting rHO-1 in BRL cells. We found that siRNA-4 was
the most potent inhibitor of HO-1 expression and activity,
and its inhibitory effect was both dose- and time-depend-
ent. To further test if siRNA-4 could suppress HO-1
The distribution of FAM-siRNA-4 in neonate rat Figure 6
The distribution of FAM-siRNA-4 in neonate rat. 
Seven-day old rats were injected intraperitoneally with FAM 
labeled siRNA-4. At 6, 24 and 48 hours after injection, the 
distribution of FAM-siRNA was observed in liver, spleen, kid-
ney, heart and lung (×60). The results localized siRNA-4 
mainly to liver and spleen. Data represent the results from 
one of three independent experiments.
The level of HO-1 protein in the liver of rats is significantly  enhanced by ALA treatment Figure 7
The level of HO-1 protein in the liver of rats is signifi-
cantly enhanced by ALA treatment. A. Protein level of 
HO-1 in the liver, B. Concentration of serum bilirubin, TBIL: 
total bilirubin; DBIL: direct bilirubin, IBIL: indirect bilirubin. 
Data represent the results from one of three independent 
experiments. Each group contained four mice.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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induced by endogenous heme in vivo, we established an
animal model of neonatal hyperbilirubinemia according
to the report of Drummond et al [3]. Seven to 9-day-old
neonatal SD rats were treated with ALA intraperitoneally.
These animals subsequently developed hyperbilirubine-
mia that mimics human hyperbilirubinemia. Injection of
siRNA-4 significantly inhibited the rHO-1 activity in the
liver and reduced the levels of serum bilirubin in the
hyperbilirubinemia rats. SnPP, as a chemical inhibitor,
could also reduce the serum bilirubin levels. However, the
indirect bilirubin of siRNA-4 treated rats decreased more
significantly. Taken together, our results suggest that
siRNA may hold for the treatment of hyperbilirubinemia
conditions in human neonates.
Although siRNA has been widely applied to therapeutic
research on various diseases, there are still many difficul-
ties that prevent its clinical application at the present time.
One of the major challenges is the stability of siRNA in
vivo. After entering the body, unmodified siRNA is quickly
degraded by endogenous nuclease [21]. Various methods
have been employed to stabilize the siRNA. For example,
certain vectors are used to synthesize cationic polymer.
Additionally, chemical modification of siRNA can
improve siRNA stability and enhance its delivery efficacy
as well as therapeutic specificity [22]. As demonstrated in
our study, the therapeutic effect of methoxy-siRNA can
last more than 48 hours after a single administration. Pre-
vious studies have shown that similar modification of
siRNA can enhance the affinity of siRNA to target
sequences, improve resistance to degradation by nuclease,
and increase the interference of a target gene [23].
Another obstacle hindering siRNA treatment progress is
that siRNA may not reach its therapeutic target or organ.
Presently, this obstacle is overcome by local administra-
tion of siRNA. For instance, siRNA targeting vascular
endothelial growth factor for age-related macular degen-
eration is delivered through retinal injection. In addition,
siRNA can treat chronic neuropathic pain through intrath-
ecal administration [24,25]. Systemic delivery of siRNA is
used to target multiple organs [26]. For example, siRNA
administrated intraperitoneally is mainly distributed in
the liver, spleen and bone marrow [26]. It is well docu-
mented that HO-1 is primarily expressed in liver and
Dosage-dependent reduction in the levels of serum bilirubin  and rHO-1 by siRNA-4 in neonatal hyperbilirubinemia rats  models Figure 8
Dosage-dependent reduction in the levels of serum 
bilirubin and rHO-1 by siRNA-4 in neonatal hyperbi-
lirubinemia rats models. A and B: The inhibitory effect of 
siRNA-4 on rHO-1 in liver increased concomitantly with 
increased injection doses. The inhibitory rates at 10 OD/20 g 
bw, 5 OD/20 g bw and 3 OD/20 g bw dosage were 42%, 30% 
and 10%, respectively. C. Effect of different dosages of 
siRNA-4 on the levels of bilirubin. *P < 0.05, compared with 
control group. Data represent the results from one of three 
independent experiments. Each group contained 4–6 mice.
Time-dependent reduction in the levels of serum bilirubin  and rHO-1 by siRNA in neonatal hyperbilirubinemia rats  models Figure 9
Time-dependent reduction in the levels of serum 
bilirubin and rHO-1 by siRNA in neonatal hyperbi-
lirubinemia rats models. A and B: The inhibitory rate of 
siRNA-4 on HO-1 protein 48 hours after injection was 33%, 
after 72 hours, it was in a time-dependent decrease. No 
inhibitory effect of siRNA on HO-1 protein was found in NC 
group. C. Effect of 10 OD/20 g bw siRNA-4 on levels of 
bilirubin at different time points. *P < 0.05, compared with 
blank group; #P < 0.05, compared with NC group. Data rep-
resent the results from one of three independent experi-
ments. Each group contained 4–6 mice.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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spleen. Thus, we selected the intraperitoneal injection as
the administration method for this study. We demon-
strated that siRNA-4 was mainly distributed in the liver
and spleen, and both serum bilirubin levels and HO-1
expression were significantly reduced in a dose- and time-
dependent manner after intraperitoneal injection of
siRNA. The maximal inhibitory effect was observed at 48
hours after single injection of siRNA. These findings are
consistent with other published studies [27].
Conclusion
Compared to the traditional phototherapy and exchange
transfusion, the mechanism of siRNA treatment is differ-
ent from the traditional methods in view of directly inhib-
iting the production of bilirubin. Our study provides a
novel rationale to treat neonatal hyperbilirubinemia via
further development of RNA interference techniques.
Methods
siRNA Design and Synthesis
Five pairs of siRNA were designed based on the rHO-1
mRNA sequence and purchased from Shanghai GeneP-
harma Co., Ltd. siRNA-1, sense 5'-CGA GGU GGG AGG
UAC UCA UTT-3', antisense 5'-AUG AGU ACC UCC CAC
CUC GTG-3'. siRNA-2, sense 5'-GGG UGA CAG AAG
AGG CUA ATT-3', antisense 5'-UUA GCC UCU UCU GUC
ACC CTG-3'. siRNA-3, sense 5'-GGG AAU UUA UGC CAU
GUA ATT-3', antisense 5'-UUA CAU GGC AUA AAU UCC
CTT-3'. siRNA-4, sense 5'-CCG UGG CAG UGG GAA
UUU ATT-3', antisense 5'-UAA AUU CCC ACU GCC ACG
GTT-3'. NC-siRNA, sense 5'-UUC UCC GAA CGU GUC
ACG UTT-3', antisense 5'-ACG UGA CAC GUU CGG AGA
ATT-3'. 5' terminal FAM labeled NC-siRNA sense strand
was used to determine siRNA transfection efficiency. All of
the siRNAs were modified by methoxy for rat injection.
Cell Culture and siRNA Delivery
BRL cells, a rat liver cell line obtained from the Shanghai
Cell Bank of the Chinese Academy of Sciences, were used
in the study. The cells were cultured in DMEM-High glu-
cose media (Invitrogen) supplemented with 10% FBS
(Hyclone Co.) at 37°C under 5% CO2. Transfection was
carried out according to the manufacturer's protocol
(Polyplus-transfection Inc.). Briefly, the cells were seeded
in a 12-well plate and cultured for 24 hours to reach 30%–
50% confluence. Each well was replaced with 1 ml fresh
media prior to transfection. Five microliters of 2 μmol/L
siRNAs were diluted with OPTI-MEM to 200 μl and were
mixed with 5 μl INTERFERIN tranfection reagent (Poly-
plus-transfection Inc.). The mixture was incubated at
room temperature for 10 minutes and was then added
into each well. After slight shaking, the cells were incu-
bated at 37°C for further experiments.
The transfection efficiency was determined using the NC-
siRNA. Cells were transfected with FAM labeled NC-siRNA
(50 nmol/L, final concentration). After 6-hour incuba-
tion, the cells were trypsinized and harvested by centrifu-
gation. The siRNA transfection efficiency was observed
under confocal microscopy and determined by flow
cytometry.
Optimization of the Dosage and Time of siRNA Delivery
Four different pairs of double-stranded siRNAs (10 nmol/
L each) were transfected into BRL cells, respectively.
Twenty-four hours later, total RNAs were isolated and
rHO-1 expression was determined by RT-PCR using
GAPDH as the internal control. Inhibitory effect of each
siRNA on rHO-1 mRNA was determined and compared.
The siRNA that exhibited the most potent inhibitory effect
was selected and transfected to BRL cells at different doses
(1, 10 and 50 nmol/L). Twenty-four hours later, the cells
Inhibiting effect of siRNA and SnPP on HO-1 in neonatal  hyperbilirubinemia rats modes Figure 10
Inhibiting effect of siRNA and SnPP on HO-1 in neo-
natal hyperbilirubinemia rats modes. A. siRNA-4 and 
SnPP were injected intraperitoneally into 7-day-old rats 
respectively, and serum total bilirubin levels decreased signif-
icantly in both group. Compared with SnPP, siRNA-4 was 
more effective at reducing indirect bilirubin. * P < 0.05, com-
pared with NC group; # P < 0.05, compared with ALA+NC-
siRNA group. B. The expression of rHO-1 in liver was ana-
lyzed by Real-Time PCR. The level of HO-1 expression in 
siRNA-4 treatment group was significantly lower than that in 
NC-siRNA group. However, the HO-1 level increased signif-
icantly in SnPP group. * P < 0.05 compared with NC group. 
Data represent the results from one of two independent 
experiments. Each group contained 6–8 mice.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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were harvested and rHO-1 expression was analyzed by RT-
PCR to determine the optimal dosage of the siRNA.
The selected siRNA with the maximum inhibitory effect
on HO-1 was transfected at the optimized dosage into
BRL cells. The rHO-1 expression was analyzed at 15, 24
and 48 hours after transfection to determine the best time
point for the inhibition.
The primer sequences used for RT-PCR analysis (synthe-
sized by Invitrogen) are as follows: HO-1  Forward: 5'-
CGG CCC TGG AAG AGG AGA TAG-3', Reverse: 5'-CGA
TGC TCG GGA AGG TGA AAA-3'. GAPDH Forward: 5'-
GTC GTG GAG TCT ACT GGC GTC TT-3', Reverse 5'-CAG
TCT TCT GAG TGG CAG TGA TGG-3'. The PCR was car-
ried out at the following condition: pre-denaturing at
94°C for 4 minutes, followed by 35 cycles of denaturing
at 94°C for 30 seconds, annealing at 60°C for 30 seconds,
and extension at 72°C for 30 seconds. For GAPDH, 28
cycles was used instead of 35. The final extension was
72°C for 10 minutes. The PCR products were checked by
agarose gel and scanned by a gel documentation system
(UVP). The results were analyzed by the quantitative soft-
ware, Labworks 4.5.
Modulation of rHO-1 Expression
BRL cells were treated with 1.5, 4.5 and 15 μmol/L hemin
for 18, 24 and 36 hours, respectively, and were then col-
lected by centrifugation at 6,000 rpm for 5 minutes. The
cells was boiled with 20 μl 2×SDS loading buffer for 10
minutes and centrifuged at 10,000 rpm for 3 minutes to
collect supernatants. Then the supernatants were sepa-
rated by 12% SDS-polyacrylamide gel and transferred to
PVDF membrane. HO-1 IgG (1:200, Sigma-Aldrich) fol-
lowed by HRP-goat anti-rabbit antibody (1:10,000,
Kangcheng Co.), and mouse anti-GAPDH antibody
(1:10,000, Kangcheng Co.) followed by HRP-goat anti-
mouse antibody (1:10,000, Kangcheng Co.) were added
on the membrane respectively, for 1 hour. rHO-1 and
GAPDH were visualized by EZ-ECL detection (Biond Co.),
and analyzed by gray scale scanning quantitation.
BRL cells were transfected with the effective dose of siRNA
for 24, 36 and 48 hours. At the end of transfection, 4.5
μmol/L hemin was added to induce the expression of HO-
1 protein for 18 hours before harvesting. The protein lev-
els were detected by Western Blot.
The rHO-1 Activity Assay
Cells seeded in a 10-cm plate were transfected with the
effective dose of siRNA-4 followed by treatment with 4.5
μmol/L hemin for 18 hours. The cells were lysed at 4°C,
and the supernatant was collected by centrifuging at
14,000 rpm for 10 minutes. Ten grams of fresh liver tissue
from SD rat (Shanghai SLAC Laboratory Animal Co.) were
added into 20 ml of 0.1 mol/L potassium phosphate
buffer (pH 7.4), homogenized, and centrifuged at 40,000
rpm for 1 hour at 4°C. The middle level aqueous phase
containing biliverdin reductase was collected. The protein
concentration was measured using BAC kit (Pierce, Rock-
ford, IL) according to manufacturer's instruction. The
enzyme-catalyzed system included 10 nmol/L hemin, 20
nmol/L β-nicotinamide adenine dinucleotide phosphate
hydrogenase (β-NADPH, Sigma-Aldrich), 1 unit/μl Glu-
cose-6-phosphate dehydrogenase (G-6-PD, Sigma-
Aldrich), 1.17 mol/L Glucose-6-phosphate (G-6-P, Sigma-
Aldrich), 25 mmol/L Magnesium Chloride (MgCl2), an
aliquot of biliverdin reductase and cell supernatant. The
reaction was carried out at 37°C for 1 hour and ceased by
ice. The samples were scanned with a spectrophotometer
(Shima-dzu, Tokyo, Japan) at absorbance from 464 to
530 nm. Bilirubin concentration was calculated based on
the change of optical density from 530 to 464 nm, with an
extinction coefficiency of 40 mmol-1cm-1. rHO-1 activity
was expressed as nanomole of bilirubin per milligram of
protein per hour (nmol bilirubin mg protein-1 h-1).
The Distribution of siRNA in Neonate Rat
The distribution of siRNA-4 was analyzed in neonate rat
to confirm targeting effect of siRNA-4 in vivo. FAM labeled
siRNA-4 was introduced into 7-day-old neonate SD rat
with 5 OD/20 g bw by intraperitoneal injection. At 6, 24
and 48 hours after injection, the animal was anesthetized
with aether and the liver, spleen, kidney, heart and lung
were immediately removed and frozen in liquid nitrogen,
then stored at -70°C. All tissues were embedded in Opti-
mal Cuttin Temperature (OCT, SAKURA, USA) and sec-
tions (7 μm) were cut from the blocks, then immediately
fixed in cold acetone for 30 minutes. Slides were stained
with DAPI and washed in PBS for three times. The distri-
bution of FAM-siRNA in each tissue was observed under
confocal microscopy (Nikon A1-R, Japan).
Establishment of Neonatal Hyperbilirubinemia Rat Model
A neonatal hyperbilirubinemia rat model was established
according to a published protocol [3]. Seven to 9-day-old
SD rats were treated intraperitoneally with ALA (Sigma-
Aldrich) for 16, 20, and 24 hours, respectively at 50 μmol/
100 g bw. These animals were breast-fed in a light-free
condition. After the development of hyperbilirubinemia,
the neonatal rats were anesthetized with ether prior to a
blood draw. For each rat, 0.5 ml of blood was drawn from
the right ventricle through the cardiac apex. The serum
was separated and preserved under light-free conditions
to determine the serum bilirubin levels (Beckman CX5
automatic biochemistry analyzer). The rats were sacrificed
by cervical dislocation. The livers were harvested, pre-
served in liquid nitrogen, and immediately processed to
assay rHO-1 level.BMC Molecular Biology 2009, 10:77 http://www.biomedcentral.com/1471-2199/10/77
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Effects of siRNA and SnPP on Neonatal 
Hyperbilirubinemia Rats Models
To optimize the effective dosage of siRNA, seven-day-old
SD rats were randomly divided into 4 groups. siRNA was
injected into three groups of mice intraperitoneally at 0, 8
and 24 hours with 3, 5 and 10 OD/20 g bw, respectively.
The control group was injected with 0.9% sodium chlo-
ride instead. ALA was injected to all the groups at 48
hours. At 72 hours, rat blood was taken to determinate the
serum bilirubin levels and liver samples were separated to
determinate the protein levels of rHO-1.
To optimize the time of siRNA treatment, seven-day-old
SD rats were randomly divided into 4 groups. The siRNA
group were treated intraperitoneally with 5 OD/20 g bw
of siRNA on day 7, 8 and 9 after birth, respectively. The
SnPP group were treated intraperitoneally with 75 μmol/
kg bw of SnPP on day 7 and 8 after birth, respectively.
Control group was injected with 0.9% sodium chloride or
NC-siRNA instead on day 7, 8 and 9 after birth. Each
group was injected with 50 μmol/100 g bw of ALA on day
9 after birth. The effect of siRNA on HO-1 was assessed
with the comparison to SnPP. Twenty-four hours after
ALA injection, the blood and liver samples were obtained
to determinate the levels of serum bilirubin and rHO-1
expression.
All animal experiments in this study received prior
approval from the Ethics Committee of Ruijin Hospital,
Medical School, Shanghai Jiaotong University under
experimental animal license SYXK (Shanghai 2008-
0050).
Mesurement of HO-1 mRNA in the Liver by Real-Time 
PCR
Rat liver samples were homogenized and total RNA was
extracted by Trizol (Invitrogen Life Technologies). Real-
time PCR was performed using an ABI Prism 7900HT
(Applied Biosysterms, Foster City, CA) according to the
manufacturer's instructions. Primers specific for GAPDH:
forward: 5'-TGC ACC ACC AAC TGC TTA G-3' and
reverse: 5'-GAT GCA GGG ATG ATG TTC-3', HO-1: for-
ward: 5'-GCT AGC CTG GTT CAA GAT AC-3' and reverse:
5'-CAA CAG GAA ACT GAG TGT GA-3'. Primers were
designed and synthesized by Invitrogen Corporation.
Reaction conditions were 2 minutes at 50°C, 10 minutes
at 95°C, followed by 40 cycles of 95°C for 15 seconds,
60°C for 1 minute and 50°C for 15 seconds, finally 60°C
for 15 seconds and 95°C for 10 minutes. The expression
of target genes was normalized to the expression of
GAPDH.
Statistical Analysis
Data were presented as the mean ± SD. Statistical compar-
isons were made by one-way ANOVA analysis in Figure 2,
3, 8, 9, 10. Student t-test was applied in Figure 5 and 7.
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